ArticleFrontiers in endocrinology2024
Association of remnant cholesterol with renal function and its progression in patients with type 2 diabetes related chronic kidney disease.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between remnant cholesterol and chronic kidney disease: Systematic review and meta-analysis.Diabetes, obesity & metabolism · 2025Pooled it
- Association of Remnant Cholesterol Levels With Kidney Replacement Therapy Initiation in Korean Patients With Chronic Kidney Disease: A Prospective Cohort Study.Journal of lipid and atherosclerosis · 2026Article
- Lipid Disorders in Patients with Renal Failure: Role in Cardiovascular Events and Progression of Chronic Kidney Disease.Life (Basel, Switzerland) · 2026Review
- Declining eGFR and Uremia Are Associated with Remnant Cholesterol Accumulation and Reduced HDL-C in Non-Dialysis Chronic Kidney Disease.Journal of clinical medicine · 2026Article
- Association between the remnant cholesterol and the risk of new-onset chronic diseases: evidence from CHARLS.Diabetology & metabolic syndrome · 2026Article
- Article
- A Narrative Review of Remnant Cholesterol as an Independent Atherogenic Lipoprotein in Type 2 Diabetes: Pathophysiology and Clinical Implications.Therapeutics and clinical risk management · 2026Review
- Association of remnant cholesterol with cardiovascular events and mortality in biopsy-proven diabetic kidney disease.Frontiers in endocrinology · 2026Article
- Article
- Role of nuclear receptors, lipid metabolism, and mitochondrial function in the pathogenesis of diabetic kidney disease.American journal of physiology. Renal physiology · 2025Review
- Effects of remnant cholesterol on adverse renal outcomes in lupus nephritis.Lipids in health and disease · 2025Observational
- Sex-specific associations of the controlling nutritional status score with diabetic kidney disease among Chinese individuals: a retrospective cross-sectional study.Frontiers in nutrition · 2025Article
- What is in a name and other peeves.Journal of diabetes · 2024Article
- Association of Remnant Cholesterol with Rapid Kidney Function Decline in Middle-Aged and Older Adults with Normal Kidney Function.Kidney diseases (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The association of Remnant cholesterol (RC) with renal function and its progression in patients with Type 2 diabetes (T2DM) related chronic kidney disease (CKD) remains unclear. Methods: 8,678 patients with T2DM-related CKD were included in cross-sectional analysis, and 6,165 patients were enrolled in longitudinal analysis and followed up for a median of 36.0 months. The outcomes were renal composite endpoint event and rapid progression of renal function. Results: 24.54% developed a renal composite endpoint event, and 27.64% rapid progression of renal function. RC levels above 0.56 mmol/L independently increased the risk of both renal composite endpoint (HR, 1.17; 95% CIs, 1.03-1.33) and rapid progression of renal function (OR, 1.17; 95% CIs, 1.01- 1.37). TG levels above 1.65 mmol/L only increased the risk of renal composite endpoint (HR, 1.16; 95% CIs, 1.02 -1.32). TC levels above 5.21 mmol/L increased the risk of renal composite endpoint (HR, 1.14; 95% CIs, 1.01-1.29) only in patients with proteinuria≥0.5g/d. Conversely, HDL-C levels below 1.20 mmol/L or above 1.84 mmol/L increased the risk of rapid progression of renal function (OR, 0.88; 95% CIs, 0.70 -0.99) in patients with proteinuria<0.5g/d (all P<0.05). Conclusion: In patients with T2DM-related CKD, RC was an independent risk factor for progression of renal function, and maintaining it below 0.56 mmol/L could reduce the risk of renal function progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.